<DOC>
	<DOCNO>NCT02284971</DOCNO>
	<brief_summary>This study evaluate combination stereotactic body radiation therapy ( SBRT ) CDX-1127 subject castration resistant prostate cancer . Subjects randomized one three arm receive SBRT prior , , conjunction first dose CDX-1127 .</brief_summary>
	<brief_title>Pilot Study SBRT CDX-1127 Prostate Cancer</brief_title>
	<detailed_description>This pilot study conduct subject metastatic prostate cancer order define whether inclusion immune regulation agent CDX-1127 augments immune response SBRT-treated primary tumor metastasis , whether inclusion CDX-1127 treatment regimen result immune response untreated metastasis .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>MAIN INCLUSION CRITERIA Males , Age ≥ 18 year . Participants must histologicallyproven prostrate adenocarcinoma castrateresistant . Progressive disease define one following : A rise PSA two successive determination least one week apart PSA level ≥2ng/ml . Softtissue progression define RECIST 1.1 . Bone disease progression define PCWG2 two new lesion bone scan . Patients must castrate level testosterone ( &lt; 50 ng/dl [ 1.74 nmol/l ] ) . Patients must undergo orchiectomy , LHRH agonists antagonist , least 3 month prior drug initiation . Patients LHRH agonists/antagonists must remain agent duration study . Clinical metastasis must present confirmed image study . Participants radiation therapy recommend prostate gland ( prostate bed nodule ) and/or bone soft tissue metastasis . SBRT may administer 14 site treatment site include prostate gland ( prostate bed nodule postprostatectomy patient ) , bone metastasis , soft tissue metastasis . Participants must least one site disease irradiate SBRT biopsied evaluate immunological outcome . ECOG performance status 02 . Adequate hepatic renal function . MAIN EXCLUSION CRITERIA Prior malignancy , affect completion interpretation study . Patients active CNS metastasis prostate cancer . Patients currently receive systemic cytotoxic chemotherapy , radiation , experimental therapy , receive therapy within precede 4 week . Patients currently receive nitrosoureas receive therapy within precede 6 week exclude . Patients currently receive systemic cytotoxic chemotherapy , radiation , experimental therapy , receive therapy within precede 4 week . Major surgery within 4 week prior start study treatment . Patients receive previously treat CDX1127 . HIV positivity Evidence active Hepatitis B virus Hepatitis C virus . Patients receive follow medication study entry within precede 4 week ( longer , otherwise specify ) exclude : 1 . Checkpoint inhibitor ( within preceding12 week ) 2 . Allergy desensitization injection 3 . Systemic corticosteroid 10 mg per day prednisone ( equivalent ) , administer parenterally orally , except physiologic replacement . Inhaled steroid ( e.g . Advair® , Flovent® , Azmacort® ) permit . Topical corticosteroid acceptable , include steroid low solubility administer nasally local effect ( e.g . Nasonex® ) 4 . Any growth factor ( e.g . GMCSF , GCSF , erythropoietin ) . 5 . Interferon interleukin therapy 6 . Other Agents putative immunomodulating activity . ( e.g . sipuleucelT ( Provenge ® ) ) Other investigational drug investigational therapy patient currently take drugs/therapy , receive drugs/therapy within 4 week prior start study treatment . Participants must prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement . Significant cardiovascular disease . Active bleeding disorder evidence chronic acute disseminate intravascular coagulation ( DIC ) . Concomitant therapeutic anticoagulation ( i.e. , warfarin ) reason venous catheter patency .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>